Nemorubicin
CAS: 108852-90-0
Ref. 3D-BN180615
1mg | 633,00 € | ||
2mg | 1.033,00 € | ||
5mg | 1.297,00 € | ||
10mg | 2.107,00 € | ||
25mg | 4.051,00 € |
Informação sobre produto
- PNU 152243
- (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[(2S)-2-methoxymorpholin-4-yl]-alpha-L-lyxo-hexopyranoside
- (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 2,3,6-trideoxy-3-[(S)-2-methoxymorpholino]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranoside
- (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-2,3,6-trideoxy-3-(2S)-2-methoxy-4-morpholinyl-.alpha.-L-lyxo-hexopyranosyloxy-, (8S,10S)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, [8S-[8α,10α(R*)]]-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
- DMM Dox
- Fce 23762
- Ver mais sinónimos
- Methoxy-Morpholynil-Doxorubicin
- Methoxymorpholinyldoxorubicin
- Mmrdx
- Pnu 152243
- (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[(2S)-2-methoxy-4-morpholinyl]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-, [8S-[8α,10α(R*)]]-
Nemorubicin is a drug that has been used in cancer gene therapy. It is stable and can form stable complexes with DNA. Nemorubicin binds to the human cytochrome P450 3A4 (CYP3A4) enzyme and blocks its activity, which may lead to an increase in the concentration of other drugs that are metabolized by CYP3A4, such as tacrolimus and cyclosporine A. Nemorubicin has been shown to be effective against solid tumours with low potency. Nemorubicin is a cytotoxic agent that inhibits protein synthesis by binding to the thymidine kinase (TK) enzyme, preventing it from converting thymidine into deoxyuridine monophosphate (dUMP). This inhibition leads to cell death by preventing DNA synthesis and repair mechanism.
Propriedades químicas
Consulta técnica sobre: 3D-BN180615 Nemorubicin
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.